Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Veralox Therapeutics, a US-based therapeutics developer exploiting technology from multiple academic research institutions, has raised $5.4m from seed investors including University of Maryland System’s Maryland Momentum Fund and University of Vermont’s Health Network. JRDF T1D Fund, managed by diabetes-focused charity JRDF, led the round with commitments from Virginia Tech Carilion (VTC) Innovation Fund and VTC Seed Fund – two VC partnerships between Virginia Tech and healthcare provider Carilion Clinic – as well as drug maker Sanofi’s Ventures unit and state-owned Maryland Technology Development Corporation. Founded in 2017, Veralox is working on inhibitors of the 12-lipoxygenase enzyme for indications including type 1 diabetes and heparin-induced thrombocytopenia and thrombosis. Its lead candidate, VLX-1005, was developed in partnership with University of California, Santa Cruz, Thomas Jefferson University, Eastern Virginia Medical School and the US government’s National Institutes of Health. The seed capital will help prepare clinical studies and identify additional target indications. Daniel Mansuri, associate director of investment at Sanofi Ventures, and Katie Ellias, managing director of JDRF T1D Fund, have joined the board of directors. Continuus Pharmaceuticals, a US-based pharmaceuticals manufacturing process developer spun out of Massachusetts Institute of Technology and drug maker Novartis, closed a $5m series B round on Friday featuring goods packaging machine supplier Industria Macchine Automatiche (IMA). The round was led by private investor Mark Bamforth and also included unspecified existing investors. Founded in 2012, Continuus has devised a drug manufacturing process that integrates active ingredient synthesis and final dosage compilation into a single process, meaning products can be supplied faster than with traditional batch production lines. It plans to contract its manufacturing services and will also build a portfolio of off-patent drug products in cooperation with pharmacies and hospitals, with the capital supporting technology development and recruitment. Mark Bamforth has joined the board of directors at Continuus, which previously closed a $2m series A round in 2014 led by IMA that included its existing investors, which had supplied a total of $395,000 of seed funding by 2013, though further historical details could not be ascertained. My Intelligent Machines (Mims), a Canada-based life sciences data analytics software developer founded from University of Quebec, has closed a C$2.6m ($2m) seed round involving syndicate Anges Québec, BetaKit reported on Friday. Anges Québec Capital, the syndicate’s affiliate fund, also contributed together with Desjardins Capital, Real Ventures, and StandUp Ventures. Founded in 2016, Mims is working on a software-as-a-service platform that uses artificial intelligence and big data to evaluate data from life…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?